CCHT is committed to growing into an open and
professional international enterprise.


Changchun High-tech Industry (Group) Co., Ltd. was established by Changchun High-tech Industry Development Corporation in June 1993, with a total share capital of 137,500,000 shares.

 

On December 18, 1996, CCHT stocks were listed at Shenzhen Stock Exchange. It is among the first batch of listed companies in northeast China.

 

Since its establishment more than 20 years ago, CCHT successfully transformed from high-tech area infrastructure construction into an enterprise group focusing on the field of medical science and technology innovation and implementing industrial investment. CCHT has adhered to the corporate culture of ‘‘innovation, concentration, generosity and sharing’’, practicing the core values of creating value for customers, creating opportunities for employees, creating benefits for shareholders and taking responsibility for the society. It has established its industrial orientation with biopharmaceutical industry as the primary and real estate industry as the supplement, has formed the development platform for three industries including genetic engineering pharmaceuticals, biological vaccines and modern traditional Chinese medicine, has realized the vigorous development pattern of ‘‘four carriages’’ including GeneScience Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘‘GenSci’’, Changchun BCHT Biotechnology Co., Ltd. (hereinafter referred to as ‘‘BCHT’’, Jilin Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as ‘‘Huakang Pharmaceutical’’) and Changchun High-tech Real Estate Development Co., Ltd. (hereinafter referred to as ‘‘High-tech Real Estate’’ and has opened up a good situation of shared development and win-win cooperation. The company's operating performance continued to grow, since 2017 for the first time into the national pharmaceutical industry top 100 list ranked 73, the ranking steadily rose in five consecutive years, respectively, 56, 45, 37, 27, 23.

 

 

Freeze-dried human rabies vaccine (human diploid cells)
The company's freeze-dried human rabies vaccine (human diploid cells) uses human diploid cells that are widely used in vaccine production internationally. The cells are derived from healthy human embryonic lung tissue, without any residual heterologous cells, and without any potential risks such as the introduction of heterologous proteins and DNA. The vaccinehas the advantages of good immunogenicity, fast onset, good safety, and lo
MORE
Fully human anti-tetanus toxin monoclonal antibody A82/B86 injection combination preparations
Tetanus is an acute traumatic infectious disease caused by the invasion of Clostridium tetani (tetanus bacillus). Currently, prevention is mainly through: tetanus vaccination to enable the body to produce acquired immunity; injection of tetanus antitoxin or tetanus human immunoglobulin to enable the body to immediately acquire immunity for the treatment of tetanus and short-term emergency prevention. Among them, monoclonal antibodies ar
MORE
GenSci098 injection
The company's GenSci098 injection is a Class Inew drug for therapeutic biological products. It is a humanized anti-TSHR antagonist monoclonal antibody that specifically binds to the thyroid stimulating hormone receptor (TSHR) to block its binding with autoantibodies to trigger the release of inflammatory factors and the production of hyaluronic acid (HA). Preclinical data show that GenSci098 has the potential to be used as a new tre
MORE
Recombinant human follicle-stimulating hormone-CTP fusion protein injection
In the field of reproductive development, male idiopathic hypogonadotropic hypogonadism (IHH) is a rare disease. Suffering from this disease will affect the patient's reproductive function and quality of life, and requires hormone replacement therapy for up to 1-2 years or even lifelong. The company's recombinant human follicle-stimulating hormone-CTP fusion protein injection is the first long-acting weekly recombinant gonadotr
MORE
GS1-144 tablets
The company's GS1-144 tablets are a Class Inew chemical drug. It is a small molecule NK3R antagonist independently developed by the company. There is no NK3R target drug on the market in China. As a non-hormonal oral therapy for menopausal vasomotor syndrome, this product can provide patients with better treatment options. During the reporting period, GS1-144 tablets launched Phase I clinical trials in China and Australia.
MORE